Dr. Edith Perez from the Mayo Clinic Cancer Center Discusses Optimizing Adjuvant Therapy
OncLive TV
Dr. Freya Schnabel from NYU School of Medicine on Predicting Breast Cancer by Atypia Type
Advertisement
Dr. Harold Harvey from Penn State Hershey Cancer Institute on Aromatase Inhibitor Treatment Duration
Dr. Brian Leyland-Jones from Winship Cancer Institute Discusses Genome Sequencing
Dr. Kenneth Bloom, from Chief Medical Officer at Clarient, Explains Situations Requiring HER2 Retesting
Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, Discusses the NeoACT Sipuleucel-T Study
Advertisement
Dr. Roman Perez-Soler, from Montefiore Medical Center, on Treatment Options for NSCLC
Dr. Sridhar Ramaswamy, from Massachusetts General Hospital Cancer Center, on Dormant Tumor Cells and Resistance
Dr. Paul Hamlin, from Memorial Sloan-Kettering Cancer Center, Discusses Integrating Brentuximab Vedotin
Dr. Barry Rosenbloom, from the Comprehensive Gaucher Treatment Center, on Gaucher Disease Diagnosis Challenges
Dr. James Berenson, from the Institute for Myeloma & Bone Cancer Research, on Zometa as the Gold Standard for MM
Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses the Stratification of Clinical Trials
Dr. Edith Perez, from the Mayo Clinic Cancer Center, Describes Retesting Recurrent Breast Cancer
Dr. Jose Baselga, from Massachusetts General Hospital, Describes the Basis Behind the BOLERO-2 Trial
Dr. Ezra Cohen, from University of Chicago, on mTOR Inhibition in Head and Neck Cancer
Dr. Michael Birrer, from Massachusetts General Hospital Cancer Center, Discusses the GOG0218 and ICON7 Trials
Dr. Sridhar Ramaswamy, from Massachusetts General Hospital Cancer Center, on Targeting Dormant Cancer Cells
Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses Targeting the mTOR Pathway
Dr. Deirdre Cohen, from NYU Medical Oncology Associates, Addresses the Role of the Hedgehog Pathway
Dr. Kenneth Bloom, the Chief Medical Officer at Clarient, Compares HER2 Screening Assays
Dr. Kevin Fox, from Abramson Cancer Center, Discusses Genomic Testing in Breast Cancer
Dr. Paul Hamlin from the Memorial Sloan-Kettering Cancer Center on Brentuximab Vedotin Pharmacology
Dr. Neal Weinreb, from University Research Foundation for Lysosomal Storage Diseases, on the Different Roles in a Gaucher Diagnosis
Dr. Ari Zimran, from Shaare Zedek Medical Center, Jerusalem, Discusses Biomarkers in Gaucher Disease
Dr. James Berenson, from the Institute for Myeloma and Bone Cancer Research, Discusses Early Phase Proteasome Inhibitors
Dr. Michael Birrer, from Massaschusetts General Hospital Cancer Center, Discusses Recurrent Ovarian Cancer Treatment
Dr. Susan O'Brien, from the MD Anderson Cancer Center, Discusses the Standard of Care for CLL
Dr. Maria Cappellini, Maggiore Hospital, Milan, Italy, on Splenectomy in Gaucher Disease Patients.
Dr. Harold Burstein, from the Dana-Farber Cancer Institute, Discusses Pathological Complete Response
Dr. Linda Vahdat, from New York-Presbyterian Hospital, Discusses the Side Effects of Halaven
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5